Karl-Erik Andersson led the review process.
Version of Record online: 21 APR 2011
Copyright © 2011 Wiley-Liss, Inc.
Neurourology and Urodynamics
Volume 30, Issue 7, pages 1227–1241, September 2011
How to Cite
Ochodnický, P., Cruz, C. D., Yoshimura, N. and Michel, M. C. (2011), Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourol. Urodyn., 30: 1227–1241. doi: 10.1002/nau.21022
Conflict of interest: none.
- Issue online: 22 AUG 2011
- Version of Record online: 21 APR 2011
- Manuscript Accepted: 21 SEP 2010
- Manuscript Received: 5 JUL 2010
- interstitial cystitits/painful bladder syndrome;
- nerve growth factor;
- overactive bladder syndrome;
- urinary biomarker
In the last two decades, nerve growth factor (NGF), initially described as a prototypical trophic factor in the development of sensory and sympathetic innervation, has emerged as a complex regulator of neural plasticity along the micturition pathways. This review aims to summarize the current experimental and clinical evidence for a role of NGF in urinary bladder. Experimental administration of NGF elicits the states of increased sensation, urgency, and bladder hyperreflexia, resembling pathologies associated with bladder overactivity and inflammatory pain, such as overactive bladder syndrome (OAB) and interstitial cystitis/painful bladder syndrome (IC/PBS). There is strong experimental evidence, including the effective therapeutic targeting, on the direct causal role of NGF in rodent models of bladder outlet obstruction, spinal cord injury, diabetic bladder dysfunction, and interstitial inflammation. In humans, there are attempts to employ urinary NGF levels as a diagnostic marker in various forms of OAB and IC/PBS. In near future, use of novel experimental tools, such as urothelium-specific NGF transgenic mice or more specific low-molecular weight NGF receptor modulators, may provide better understanding of several unresolved issues in NGF-related bladder dysfunction. Moreover, successful experimental therapeutic approaches, such as NGF sequestering proteins or modified NGF antibodies, await the translation to the clinical treatment of bladder disorders. Neurourol. Urodynam. 30:1227–1241, 2011. © 2011 Wiley-Liss, Inc.